Coronary/Structural Heart

Micro Interventional Devices, Inc.™ Successfully Treats First-in-Human Patient with Percutaneous MIA™, Minimally Invasive Annuloplasty Technology

NEWTOWN, Pa., Oct. 12, 2018 /PRNewswire/ — Micro Interventional Devices, Inc.™ (MID) announced today the world’s first percutaneous implantation of its MIA™, Minimally Invasive Annuloplasty, technology for tricuspid and mitral repair.  This marks the first patient enrolled in the transcatheter arm of the STTAR (Study of Transcatheter Tricuspid Annular Repair) trial being conducted in Europe. […]

CHF Solutions Initiates Strategic Collaboration with NI Medical on Management of Fluid Overloaded Patients

EDEN PRAIRIE, Minn., Oct. 11, 2018 (GLOBE NEWSWIRE) — CHF Solutions, Inc. (Nasdaq: CHFS) announced today that it has entered into a collaboration agreement with NI Medical to explore potential clinical synergies between the company’s Aquadex FlexFlow® System and NI Medical’s NICaS Hemodynamic Navigator to assess patient’s fluid volume status and […]

Transseptal Solutions Announces FDA Clearance of Its Novel Transseptal Access System for Transseptal Puncture and Left Atrial Navigation

NETANYA, Israel, October 11, 2018 /PRNewswire/ — Transseptal Solutions Ltd., developer of an innovative Transseptal Access System with a novel approach of transseptal puncture and left atrial navigation to introduce various cardiovascular catheters into the left heart chambers, announced today that the company has received FDA 510(k) clearance for the TSP Crosser[TM] Transseptal Access System. […]

Neovasc Reducer™ Granted Breakthrough Device Designation from FDA

VANCOUVER, Oct. 10, 2018 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that the U.S. Food and Drug Administration (the “FDA”) […]

Bellerophon Provides Update on INOpulse® Phase 2b Clinical Program for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

WARREN, N.J., Oct. 09, 2018 (GLOBE NEWSWIRE) — Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today provided an update on the Company’s ongoing Phase 2b randomized, double-blind, placebo-controlled clinical study (iNO-PF) evaluating INOpulse® in patients with Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD), as […]

Edwards Announces Start Of U.S. Study Of Self-Expanding Transcatheter Heart Valve

IRVINE, Calif., Oct. 8, 2018 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that it has commenced the U.S. pivotal trial that will study its self-expanding CENTERA transcatheter valve for severe, symptomatic aortic stenosis (AS) patients at intermediate […]

Vizient, Inc. Announces Moving Analytics as the 2018 Innovation Challenge Winner

IRVING, Texas–(BUSINESS WIRE)–Vizient, Inc. today announced Moving Analytics as the winner of its 2018 Innovation Challenge, an interactive competition between four early-stage growth health care companies. The competition was held on Wednesday, Oct. 3, during the opening session of the Vizient Clinical Connections Summit in Las Vegas. The Innovation Challenge is an interactive pitch […]

Eidos Therapeutics to Present Phase 2 Data for AG10 in TTR Amyloidosis Cardiomyopathy at the AHA 2018 Scientific Sessions in a Late-Breaking Featured Science Oral Presentation

SAN FRANCISCO, Oct. 05, 2018 (GLOBE NEWSWIRE) — Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today announced that results of its Phase 2 clinical trial studying AG10 in subjects with symptomatic transthyretin (TTR) amyloidosis cardiomyopathy (ATTR-CM) will be announced in a late-breaking featured science oral presentation at this year’s American Heart Association […]

V-Wave Announces Enrollment of First Patients in RELIEVE-HF Pivotal Trial of its Heart Failure Therapy

CAESAREA, Israel, Oct. 3, 2018 /PRNewswire/ — V-Wave Ltd. announced today that it has enrolled the first patients in its global, 500 patient pivotal study of its proprietary, minimally invasive implanted interatrial shunt device for treating patients with NHYA Class III and ambulatory Class IV symptomatic heart failure (HF).  This randomized, controlled, double-blinded […]

Zenosense, Inc.: MIDS Medical Expands Technical Team

VALENCIA, SPAIN, Oct. 02, 2018 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Zenosense, Inc. (OTCQB: ZENO, “Zenosense”, the “Company”), a healthcare technology company focused on the development and commercialization of the MIDS Cardiac™ hand-held technology for the early detection of heart attack at the Point of Care, is pleased to announce […]